The FTC issued an administrative complaint to block Omnicare’s bid for a hostile acquisition of its biggest and only U.S. rival, PharMerica. Omnicare and PharMerica are long-term care pharmacies, which work with institutional providers like skilled nursing facilities. The FTC believes that the merger would allow Omnicare to raise the price of drugs for Medicare Part D because the number of skilled nursing facilities receiving services from Omnicare would “dramatically increas[e],” thereby also increasing Omnicare’s bargaining power to raise the price of drugs to Part D health plans.
Featured News
Eighth Circuit to Hear Appeal of Major Real Estate Antitrust Settlement
Jan 14, 2026 by
CPI
Netflix Prepares All-Cash Bid for Warner Bros Discovery Studios and Streaming Assets
Jan 14, 2026 by
CPI
Draft Budget Bills Would Slash Trump Administration’s Tech-Funding Requests
Jan 14, 2026 by
CPI
Shadow AI Emerges as the New Front Line in GenAI Compliance
Jan 14, 2026 by
CPI
Google Asks Judge to Reject Media Company Claims Over AI Search Overviews
Jan 14, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi